Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
0.561
+0.031 (5.89%)
Mar 9, 2026, 3:37 PM EDT - Market open
Xilio Therapeutics Employees
Xilio Therapeutics had 64 employees as of December 31, 2024. The number of employees decreased by 9 or -12.33% compared to the previous year.
Employees
64
Change (1Y)
-9
Growth (1Y)
-12.33%
Revenue / Employee
$496,938
Profits / Employee
-$913,891
Market Cap
41.22M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 64 | -9 | -12.33% |
| Dec 31, 2023 | 73 | -16 | -17.98% |
| Dec 31, 2022 | 89 | 15 | 20.27% |
| Dec 31, 2021 | 74 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 70 |
| NextCure | 43 |
| Palatin Technologies | 29 |
| Lisata Therapeutics | 26 |
| Veru Inc. | 20 |
| Lipocine | 16 |
| Atossa Therapeutics | 15 |
| CervoMed | 15 |
XLO News
- 7 days ago - Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 7 days ago - Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 25 days ago - Xilio Therapeutics Announces Pricing of Underwritten Offering - GlobeNewsWire
- 2 months ago - Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates - GlobeNewsWire
- 4 months ago - Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results - GlobeNewsWire
- 4 months ago - Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC Transcript - Seeking Alpha
- 4 months ago - Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting - GlobeNewsWire
- 4 months ago - Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting - GlobeNewsWire